A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat.
about
Obesity and cancer, a case for insulin signalingOn the metabolically active form of metaglidasen: improved synthesis and investigation of its peculiar activity on peroxisome proliferator-activated receptors and skeletal musclesFibrates, glitazones, and peroxisome proliferator-activated receptorsChronic and acute effects of thiazolidinediones BM13.1258 and BM15.2054 on rat skeletal muscle glucose metabolismRosiglitazone restores renal D1A receptor-Gs protein coupling by reducing receptor hyperphosphorylation in obese ratsCellular mechanisms of insulin resistanceEffect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected].Lipid lowering explains the insulin sensitivity enhancing effects of a thiazolidinedione, 5-(4-(2-(2-phenyl-4-oxazolyl)ethoxy)benzyl)-2,4 thiazolidinedione.The emerging role of thiazolidinediones in the treatment of diabetes-mellitus and related disorders.Thiazolidinediones: a new class of antidiabetic drugs.Rosiglitazone enhances apolipoprotein M (Apom) expression in rat's liverInsulin sensitiser drugs.Development of Therapeutics That Induce Mitochondrial Biogenesis for the Treatment of Acute and Chronic Degenerative Diseases.Where thiazolidinediones will fit.Molecular insights into insulin action and secretion.Redefining the clinical management of type 2 diabetes: matching therapy to pathophysiology.Hepatic glucose production: therapeutic target in type 2 diabetes?Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect.The clinical biochemistry of obesity.Can the electrophysiological action of rosiglitazone explain its cardiac side effects?A phase II clinical trial to investigate the effect of pioglitazone on (18)F-FDG uptake in malignant lesions.LipiD-QuanT: a novel method to quantify lipid accumulation in live cells.Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis.Nonischemic heart failure in diabetes mellitus.Troglitazone suppresses glutamine metabolism through a PPAR-independent mechanism.PPAR-gamma activation fails to provide myocardial protection in ischemia and reperfusion in pigs.Viewing FOP through rosi-colored glasses.Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinedionesPilot study of pioglitazone and exercise training effects on basal myocardial substrate metabolism and left ventricular function in HIV-positive individuals with metabolic complications.Identification of a novel selective PPARγ ligand with a unique binding mode and improved therapeutic profile in vitro.Insulin-sensitizing action of rosiglitazone is enhanced by preventing hyperphagia.AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats.PPARγ signaling and emerging opportunities for improved therapeutics.Autophagy: controlling cell fate in rheumatic diseases.Oncostatic activity of a thiazolidinedione derivative on human androgen-dependent prostate cancer cells.PPARs and lipid ligands in inflammation and metabolism.Multiunit floating drug delivery system of rosiglitazone maleate: development, characterization, statistical optimization of drug release and in vivo evaluation.Screening of saponins and sapogenins from Medicago species as potential PPARγ agonists and X-ray structure of the complex PPARγ/caulophyllogenin.Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution.Pioglitazone improves superoxide dismutase mediated vascular reactivity in the obese Zucker rat.
P2860
Q26771452-2781F583-38D5-435D-BAF2-8301C7F18083Q27697692-8AE752E2-40FA-4B4F-B6E9-DB9EA79B4D63Q28279732-44A2C36A-864F-4F60-8AEF-4AAC26C8561CQ28343733-41F298D0-B39F-46F1-BCF0-85A1D1AC3BB8Q28567576-5579A1F3-9112-4D8B-ACC9-D408D4626671Q29619549-0530F4E7-1EC2-413C-85F4-1006776FE8C7Q30738419-4B2C5047-5115-449F-91A0-96C75B9B3B9BQ32061029-047433CB-AC02-45CA-9473-FF76C166E877Q33537653-9DA6DE2A-91CA-42E8-B512-CAD628861941Q33607634-FF895B53-F2F9-4A06-8DDC-D010FB2F2B35Q34054911-050E029F-1930-4D3D-8637-355FBF31F681Q34074912-43B48F72-8488-4F28-8951-907C55265ED0Q34538482-E6082097-69E0-46B3-9A08-235CEED7035AQ34580999-AFFFE355-5E7A-4ED9-BC4E-8E6A49F31DC6Q34655565-28347D12-1DF8-4AED-A9F0-94612E7B6E87Q34655587-39D2F69F-790B-4724-92E8-BC1BEFFFE31FQ34722593-A973B5C2-0409-4FB9-9D2E-0EABC5995B76Q35750683-00B28767-A49A-4265-9175-BD49B144697AQ35819237-CC381EDE-EBA2-418C-AC6A-C5AA2A2968EDQ36032128-296D856E-F214-4F10-932C-1204A6F2480FQ36094168-3DF5C429-99EC-4DE8-9DDC-704E99F09C5AQ36197876-4F49DC4D-3C86-4997-9C4C-EF52E135F7ABQ36580568-3956E37D-E148-437E-B0F5-45A630B45CDDQ36762969-0EF4A3A9-CF83-4333-9834-0DC0C226EFE0Q36776406-15A15E21-E9B3-43CB-938A-A0046D50F696Q36787677-8848646F-872A-46EF-ACAB-0BD6EA2E1FC2Q37118989-C94AEB67-7044-4AF5-A8C7-BC042A8A0534Q37271252-056CB46A-0A38-490C-96C0-A6BD0204A792Q37602891-84FE4824-D442-45F7-A707-E3276E3F82CDQ37609686-209B8D95-C121-4D0D-BC2D-8FFE51877C17Q38299766-DF7155F8-1D7C-4947-B492-58670367B458Q38361567-C25AA863-0D43-4190-8C33-3CD4CCC200A4Q38856983-87D4C2B8-9249-4751-B159-1B4B963531DDQ38873681-A2275639-6AB3-41A2-B4EA-1AB232384C68Q40807764-AB01ADA5-13A7-4FC0-8B88-85DE3BD81230Q41763780-5E1DBE30-4209-472E-AEC9-A5C99F6371F1Q41775443-F711406E-1801-4153-9116-653B159EF398Q41826885-19ABD26A-CB97-42AB-A6D7-551FC3F49B38Q41853507-591E703B-654B-4911-B74E-389438A4C4BBQ43109238-EF48443C-DF54-4ED7-A899-0B5ADEAFBEE7
P2860
A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat.
description
1994 nî lūn-bûn
@nan
1994 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
A new antidiabetic agent, BRL ...... nd glucoregulation in the rat.
@ast
A new antidiabetic agent, BRL ...... nd glucoregulation in the rat.
@en
A new antidiabetic agent, BRL ...... nd glucoregulation in the rat.
@nl
type
label
A new antidiabetic agent, BRL ...... nd glucoregulation in the rat.
@ast
A new antidiabetic agent, BRL ...... nd glucoregulation in the rat.
@en
A new antidiabetic agent, BRL ...... nd glucoregulation in the rat.
@nl
prefLabel
A new antidiabetic agent, BRL ...... nd glucoregulation in the rat.
@ast
A new antidiabetic agent, BRL ...... nd glucoregulation in the rat.
@en
A new antidiabetic agent, BRL ...... nd glucoregulation in the rat.
@nl
P2093
P356
P1433
P1476
A new antidiabetic agent, BRL ...... nd glucoregulation in the rat.
@en
P2093
Chisholm DJ
Jenkins AB
Kennedy CJ
Kraegen EW
Laybutt DR
P304
P356
10.2337/DIAB.43.10.1203
P407
P577
1994-10-01T00:00:00Z